Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2018 · 10-Q
Revenue—
Net Income-$235.78M-$235.78MN/M vs Q3 2017 EPS Diluted-$4.70-$4.70N/M vs Q3 2017 Operating Income-$234,660,000N/M Operating Cash Flowderived-$3,433,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,435,000N/M ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end